| Aug 16 |
5 Small Drug Stocks to Buy as Innovation Reaches Peak
|
| Aug 8 |
Foghorn Therapeutics GAAP EPS of -$0.45, revenue of $6.88M
|
| Aug 8 |
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
|
| Aug 6 |
Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner
|
| Jul 29 |
Institutional investors own a significant stake of 36% in Foghorn Therapeutics Inc. (NASDAQ:FHTX)
|
| May 28 |
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
|
| May 23 |
Foghorn Therapeutics raises ~$110 Million through direct offering
|
| May 22 |
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
|
| May 20 |
Foghorn prices $110M mixed-shelf registered direct offering
|
